

# Johanna C Kluin-Nelemans

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8434542/johanna-c-kluin-nelemans-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

182  
papers

10,501  
citations

50  
h-index

99  
g-index

183  
ext. papers

11,918  
ext. citations

5.9  
avg, IF

5.35  
L-index

#	Paper	IF	Citations
182	Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group.. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2022</b> ,	5.4	5
181	Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal.. <i>HemaSphere</i> , <b>2021</b> , 5, e646	0.3	16
180	Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2021</b> , 9, 1705-1712.e4	5.4	3
179	Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis. <i>Journal of Investigative Dermatology</i> , <b>2021</b> , 141, 1719-1727	4.3	4
178	The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial. <i>International Journal of Cancer</i> , <b>2021</b> , 148, 150-160	7.5	4
177	Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 487-498	5.4	4
176	LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome. <i>Blood</i> , <b>2021</b> , 137, 3251-3258	2.2	1
175	Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis. <i>Theranostics</i> , <b>2021</b> , 11, 292-303	12.1	9
174	Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis. <i>Leukemia</i> , <b>2021</b> ,	10.7	5
173	Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , <b>2021</b> , 8, e648-e657	14.6	6
172	A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial.. <i>Cancers</i> , <b>2021</b> , 14,	6.6	1
171	Importance of Adequate Diagnostic Workup for Correct Diagnosis of Advanced Systemic Mastocytosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2020</b> , 8, 3121-3127.e1	5.4	8
170	Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions. <i>Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 146, 300-306	11.5	15
169	Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial. <i>British Journal of Haematology</i> , <b>2020</b> , 190, 385-393	4.5	6
168	Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 146, 356-366.e4	11.5	15
167	Late relapses in diffuse large B-cell lymphoma: where to move next?. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 1005-1006	1.9	
166	Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 75, 1927-1938	9.3	15

165	Interim thymus and activation regulated chemokine versus interim F-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation. <i>British Journal of Haematology</i> , <b>2020</b> , 190, 40-44	4.5	9
164	Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry. <i>Leukemia</i> , <b>2020</b> , 34, 1090-1101	10.7	12
163	Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 248-256	2.2	29
162	Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts. <i>Theranostics</i> , <b>2020</b> , 10, 10743-10768	12.1	40
161	Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2019</b> , 7, 1125-1133.e1	5.4	106
160	Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network. <i>British Journal of Haematology</i> , <b>2019</b> , 184, 616-624	4.5	16
159	Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study. <i>Health and Quality of Life Outcomes</i> , <b>2019</b> , 17, 115	3	9
158	International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. <i>Lancet Haematology</i> , <b>2019</b> , 6, e638-e649	14.6	42
157	Reasons for low uptake of a psychological intervention offered to cancer survivors with elevated depressive symptoms. <i>Psycho-Oncology</i> , <b>2019</b> , 28, 830-838	3.9	6
156	Long-Term Outcome of Patients With a Hematologic Malignancy and Multiple Organ Failure Admitted at the Intensive Care. <i>Critical Care Medicine</i> , <b>2019</b> , 47, e120-e128	1.4	14
155	KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis. <i>Leukemia</i> , <b>2019</b> , 33, 1124-1134	10.7	17
154	Time trend analysis of long term outcome of patients with haematological malignancies admitted at dutch intensive care units. <i>British Journal of Haematology</i> , <b>2018</b> , 181, 68-76	4.5	9
153	What is the optimal initial management of the older MCL patient?. <i>Best Practice and Research in Clinical Haematology</i> , <b>2018</b> , 31, 99-104	4.2	7
152	Relapse in stage I(E) diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , <b>2018</b> , 36, 416-421	1.3	5
151	Midostaurin in patients with indolent systemic mastocytosis: An open-label phase 2 trial. <i>Journal of Allergy and Clinical Immunology</i> , <b>2018</b> , 142, 1006-1008.e7	11.5	24
150	Treatment of initial parenchymal central nervous system involvement in systemic aggressive B-cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 1-6	1.9	12
149	Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. <i>Cancer Research</i> , <b>2017</b> , 77, 1261-1270	10.1	162
148	No outcome disparities in patients with diffuse large B-cell lymphoma and a low socioeconomic status. <i>Cancer Epidemiology</i> , <b>2017</b> , 48, 110-116	2.8	4

147	Management around invasive procedures in mastocytosis: An update. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2017</b> , 119, 304-309	3.2	25
146	MYC expression and translocation analyses in low-grade and transformed follicular lymphoma. <i>Histopathology</i> , <b>2017</b> , 71, 960-971	7.3	16
145	Impact of Vitamin K Antagonists on Quality of Life in a Prospective Cohort of 807 Atrial Fibrillation Patients. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2016</b> , 9, 388-94	5.8	7
144	Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 2530-41	59.2	269
143	Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. <i>Journal of Allergy and Clinical Immunology</i> , <b>2016</b> , 137, 35-45	11.5	209
142	Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma (pTNHL) of the elderly: Final results of 116 patients treated in the international ACT-2 phase III trial.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 7500-7500	2.2	11
141	Exome Sequencing in Classic Hairy Cell Leukaemia Reveals Widespread Variation in Acquired Somatic Mutations between Individual Tumours Apart from the Signature BRAF V(600)E Lesion. <i>PLoS ONE</i> , <b>2016</b> , 11, e0149162	3.7	11
140	Risk of Bleeding and Thrombosis in Patients 70 Years or Older Using Vitamin K Antagonists. <i>JAMA Internal Medicine</i> , <b>2016</b> , 176, 1176-83	11.5	21
139	Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1386-94	2.2	197
138	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 1348-1356	4.7	51
137	Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. <i>Haematologica</i> , <b>2016</b> , 101, 1133-1143	6.6	46
136	Clinical profile and recurrence rate in women with venous thromboembolism during combined hormonal contraceptive use: a prospective cohort study. <i>British Journal of Haematology</i> , <b>2016</b> , 172, 636-45	4.5	2
135	Diminished reliability of tryptase as risk indicator of mastocytosis in older overweight subjects. <i>Journal of Allergy and Clinical Immunology</i> , <b>2015</b> , 135, 792-8	11.5	9
134	Splenectomy and second malignancies in patients with Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 230-1	1.9	3
133	Paediatric nodal marginal zone B-cell lymphadenopathy of the neck: a Haemophilus influenzae-driven immune disorder?. <i>Journal of Pathology</i> , <b>2015</b> , 236, 302-14	9.4	18
132	Long-term quality of VKA treatment and clinical outcome after extreme overanticoagulation in 14,777 AF and VTE patients. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 113, 881-90	7	9
131	Cardiovascular disease after treatment for Hodgkin lymphoma: an analysis of nine collaborative EORTC-LYSA trials. <i>Lancet Haematology</i> , <b>2015</b> , 2, e492-502	14.6	90
130	Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1338-46	2.2	112

129	Variant B cell receptor isotype functions differ in hairy cell leukemia with mutated BRAF and IGHV genes. <i>PLoS ONE</i> , <b>2014</b> , 9, e86556	3.7	6
128	Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study. <i>British Journal of Haematology</i> , <b>2014</b> , 165, 489-96	4.5	47
127	Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome. <i>Leukemia and Lymphoma</i> , <b>2014</b> , 55, 526-32	1.9	36
126	CD30 in systemic mastocytosis. <i>Immunology and Allergy Clinics of North America</i> , <b>2014</b> , 34, 341-55	3.3	18
125	Tumor Cell Proliferation (Ki-67 Index) Overcomes Cytology and Growth Pattern As Prognostic Factor in Mantle-Cell Lymphoma [Results from Randomized Trials of the European MCL Network. <i>Blood</i> , <b>2014</b> , 124, 2977-2977	2.2	4
124	Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial. <i>Blood</i> , <b>2014</b> , 124, 636-636	2.2	12
123	The prevalence of underlying bleeding disorders in patients with heavy menstrual bleeding with and without gynecologic abnormalities. <i>American Journal of Obstetrics and Gynecology</i> , <b>2013</b> , 209, 202.e1-7	6.4	33
122	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). <i>Annals of Oncology</i> , <b>2013</b> , 24, 561-76	10.3	162
121	Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 699-707	1.9	32
120	Pain and anxiety during bone marrow biopsy. <i>Pain Management Nursing</i> , <b>2013</b> , 14, 310-317	2.5	15
119	Higher mast cell load decreases the risk of Hymenoptera venom-induced anaphylaxis in patients with mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2013</b> , 132, 125-30	11.5	65
118	Prevalence of indolent systemic mastocytosis in a Dutch region. <i>Journal of Allergy and Clinical Immunology</i> , <b>2013</b> , 131, 1429-31.e1	11.5	57
117	Management of mantle cell lymphoma in the elderly patient. <i>Clinical Interventions in Aging</i> , <b>2013</b> , 8, 1229-36	4.36	9
116	Durable Responses and Improved Quality Of Life With Midostaurin (PKC412) In Advanced Systemic Mastocytosis (SM): Updated Stage 1 Results Of The Global D2201 Trial. <i>Blood</i> , <b>2013</b> , 122, 106-106	2.2	6
115	Increased risk of arterial thromboembolism after a prior episode of venous thromboembolism: results from the Prevention of RENal and Vascular END stage Disease (PREVEND) Study. <i>British Journal of Haematology</i> , <b>2012</b> , 159, 216-22	4.5	9
114	European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. <i>Wiener Klinische Wochenschrift</i> , <b>2012</b> , 124, 807-14	2.3	26
113	The risk of postpartum hemorrhage in women using high dose of low-molecular-weight heparins during pregnancy. <i>Thrombosis Research</i> , <b>2012</b> , 130, 334-8	8.2	37
112	Clinical and pathological features of testicular diffuse large B-cell lymphoma: a heterogeneous disease. <i>Leukemia and Lymphoma</i> , <b>2012</b> , 53, 242-6	1.9	11

111	Haemostatic variables during normal menstrual cycle. A systematic review. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 107, 22-9	7	45
110	Lipid levels do not influence the risk of venous thromboembolism. Results of a population-based cohort study. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 108, 923-9	7	24
109	PROS1 Heerlen polymorphism is associated with increased free plasma tissue factor pathway inhibitor levels. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 107, 594-6	7	2
108	Elevated albuminuria associated with increased risk of recurrent venous thromboembolism: results of a population-based cohort study. <i>British Journal of Haematology</i> , <b>2012</b> , 156, 667-71	4.5	10
107	Premature ovarian failure and fertility in long-term survivors of Hodgkin lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 291-9	2.2	77
106	Parenthood in survivors of Hodgkin lymphoma: an EORTC-GELA general population case-control study. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3854-63	2.2	22
105	Cell Proliferation (Ki-67) As Prognostic Marker in Mantle Cell Lymphoma.. <i>Blood</i> , <b>2012</b> , 120, 2677-2677	2.2	2
104	KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial. <i>Blood</i> , <b>2012</b> , 120, 799-799	2.2	15
103	Prognostic Importance of Comorbidity in a Population-Based Analysis of Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP. <i>Blood</i> , <b>2012</b> , 120, 3656-3656	2.2	3656
102	Decreased free protein S levels and venous thrombosis in the acute setting, a case-control study. <i>Thrombosis Research</i> , <b>2011</b> , 128, 501-2	8.2	7
101	Treatment of elderly patients with mantle cell lymphoma. <i>Seminars in Hematology</i> , <b>2011</b> , 48, 208-13	4	21
100	Active cytomegalovirus infection in patients with acute venous thrombosis: a case-control study. <i>American Journal of Hematology</i> , <b>2011</b> , 86, 510-2	7.1	16
99	Reply to Z. Blumenfeld. <i>Hematological Oncology</i> , <b>2011</b> , 29, 53-53	1.3	
98	Junior Scientific Masterclass: Additional Science Training for Medical Students. <i>Medical Science Educator</i> , <b>2011</b> , 21, 86-90	0.7	0
97	Double-hit B-cell lymphomas. <i>Blood</i> , <b>2011</b> , 117, 2319-31	2.2	515
96	Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network. <i>Leukemia and Lymphoma</i> , <b>2011</b> , 52, 2226-36	1.9	27
95	Erythropoietin is reduced by combination of diuretic therapy and RAAS blockade in proteinuric renal patients with preserved renal function. <i>Nephrology Dialysis Transplantation</i> , <b>2010</b> , 25, 3256-60	4.3	10
94	Routine evaluation and treatment of unexplained menorrhagia: do we consider haemostatic disorders?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , <b>2010</b> , 152, 191-4	2.4	6

93	Associations between high factor VIII and low free protein S levels with traditional arterial thrombotic risk factors and their risk on arterial thrombosis: results from a retrospective family cohort study. <i>Thrombosis Research</i> , <b>2010</b> , 126, e249-54	8.2	9
92	In normal controls, both age and gender affect coagulability as measured by thrombelastography. <i>Anesthesia and Analgesia</i> , <b>2010</b> , 110, 987-94	3.9	73
91	Thrombocytopenia affects plasmatic coagulation as measured by thrombelastography. <i>Blood Coagulation and Fibrinolysis</i> , <b>2010</b> , 21, 389-97	1	23
90	Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. <i>Blood</i> , <b>2010</b> , 115, 3215-23	2.2	200
89	The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non-mast cell lineage disease (SM-AHNMD). <i>Blood</i> , <b>2010</b> , 116, 850-1	2.2	17
88	Low cut-off values increase diagnostic performance of protein S assays. <i>Thrombosis and Haemostasis</i> , <b>2010</b> , 104, 618-25	7	12
87	Characterisation of hairy cell leukaemia by tiling resolution array-based comparative genome hybridisation: a series of 13 cases and review of the literature. <i>European Journal of Haematology</i> , <b>2010</b> , 84, 17-25	3.8	13
86	Fertility preservation after chemotherapy for Hodgkin lymphoma. <i>Hematological Oncology</i> , <b>2010</b> , 28, 168-79	1.3	62
85	Effects of red blood cells on hemostasis. <i>Transfusion</i> , <b>2010</b> , 50, 1536-44	2.9	29
84	Sperm quality before treatment in patients with early stage Hodgkin lymphoma enrolled in EORTC-GELA Lymphoma Group trials. <i>Haematologica</i> , <b>2009</b> , 94, 1691-7	6.6	63
83	High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. <i>British Journal of Haematology</i> , <b>2009</b> , 144, 524-30	4.5	57
82	Lenalidomide therapy in systemic mastocytosis. <i>Leukemia Research</i> , <b>2009</b> , 33, e19-22	2.7	13
81	Quality of life after successful treatment of early-stage Hodgkin lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. <i>Lancet Oncology, The</i> , <b>2009</b> , 10, 1160-70	21.7	80
80	Genome wide molecular analysis of minimally differentiated acute myeloid leukemia. <i>Haematologica</i> , <b>2009</b> , 94, 1546-54	6.6	11
79	High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin. <i>Thrombosis and Haemostasis</i> , <b>2009</b> , 101, 93-99	7	87
78	Comorbidity at Relapse Is An Independent Predictor for Eligibility and Outcome of Autologous Stem Cell Transplantation in Aggressive Non-Hodgkin Lymphoma.. <i>Blood</i> , <b>2009</b> , 114, 2313-2313	2.2	
77	Results of bone marrow examination in 275 patients with histological features that suggest an indolent type of cutaneous B-cell lymphoma. <i>British Journal of Haematology</i> , <b>2008</b> , 142, 52-6	4.5	53
76	A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. <i>Blood</i> , <b>2008</b> , 111, 558-65	2.2	676

75	Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. <i>Blood</i> , <b>2008</b> , 111, 2581-8	2.2	23
74	EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. <i>Blood</i> , <b>2008</b> , 112, 1039-41	2.2	41
73	Biochemical markers predictive for bone marrow involvement in systemic mastocytosis. <i>Haematologica</i> , <b>2008</b> , 93, 120-3	6.6	13
72	An improved flow cytometric method using FACS Lysing Solution for measurement of ZAP-70 expression in B-cell chronic lymphocytic leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , <b>2008</b> , 74, 40-4	3.4	8
71	A pre-induction course with non-cross-reacting cytostatic drugs for rapid tumour load reduction improves outcome in adult acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , <b>2007</b> , 138, 275-7	4.5	2
70	Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis. <i>Journal of Immunology</i> , <b>2007</b> , 178, 2287-95	5.3	78
69	Gonadal function in males after chemotherapy for early-stage Hodgkin lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 2825-32	2.2	81
68	High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis. <i>Cancer Treatment Reviews</i> , <b>2007</b> , 33, 338-46	14.4	73
67	Chemotherapy plus involved-field radiation in early-stage Hodgkin disease. <i>New England Journal of Medicine</i> , <b>2007</b> , 357, 1916-27	59.2	324
66	Combined-modality therapy for clinical stage I or II Hodgkin lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 3128-35	2.2	180
65	Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 4135-42	2.2	131
64	Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. <i>Blood</i> , <b>2006</b> , 107, 2912-9	2.2	115
63	The pathogenesis of venous thromboembolism: evidence for multiple interrelated causes. <i>Annals of Internal Medicine</i> , <b>2006</b> , 145, 807-15	8	55
62	Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2006</b> , 66, 1168-77	4	18
61	Late non-neoplastic events in patients with aggressive non-Hodgkin lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials. <i>Clinical Lymphoma and Myeloma</i> , <b>2005</b> , 6, 122-30		44
60	Treatment and survival of patients with thyroid lymphoma: a population-based study with clinical and pathologic reviews. <i>Clinical Lymphoma and Myeloma</i> , <b>2005</b> , 6, 240-7		5
59	HLA antigens and post renal transplant lymphoproliferative disease: HLA-B matching is critical. <i>Transplantation</i> , <b>2005</b> , 80, 595-9	1.8	38
58	Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. <i>Blood</i> , <b>2005</b> , 105, 2916-23	2.2	75



57	Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. <i>Blood</i> , <b>2005</b> , 105, 2677-84	2.2	443
56	Early onset post-transplant lymphoproliferative disease is associated with allograft localization. <i>Clinical Transplantation</i> , <b>2005</b> , 19, 327-34	3.8	75
55	Difference in absolute risk of venous and arterial thrombosis between familial protein S deficiency type I and type III. Results from a family cohort study to assess the clinical impact of a laboratory test-based classification. <i>British Journal of Haematology</i> , <b>2005</b> , 128, 703-10	4.5	33
54	Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study. <i>Annals of Hematology</i> , <b>2005</b> , 84, 311-6	3	28
53	Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin@ lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 3793-801	2.2	20
52	PTLD Visualization by FDG-PET: Improved Detection of Extranodal Localizations and Response Monitoring.. <i>Blood</i> , <b>2005</b> , 106, 5389-5389	2.2	
51	The role of B cell-mediated T cell costimulation in the efficacy of the T cell retargeting bispecific antibody BIS20x3. <i>Journal of Immunology</i> , <b>2004</b> , 173, 6009-16	5.3	2
50	The European Competence Network on Mastocytosis (ECNM). <i>Wiener Klinische Wochenschrift</i> , <b>2004</b> , 116, 647-51	2.3	19
49	Unique polycomb gene expression pattern in Hodgkin@ lymphoma and Hodgkin@ lymphoma-derived cell lines. <i>American Journal of Pathology</i> , <b>2004</b> , 164, 873-81	5.8	113
48	Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups. <i>Blood</i> , <b>2004</b> , 103, 4408-15	2.2	31
47	The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. <i>Blood</i> , <b>2004</b> , 104, 143-8	2.2	94
46	High Rates of Molecular Response and Low Incidence of Mutations in Patients Treated with Newly Diagnosed Chronic Myeloid Leukemia (CML) Treated with a Dose-Escalated Combination of Imatinib and Cytarabin.. <i>Blood</i> , <b>2004</b> , 104, 19-19	2.2	2
45	Hereditary Protein S Type III Deficiency Is Not a Risk Factor for Venous and Arterial Thrombosis, in Contrast to Protein S Deficiency Type I. Results from a Family Cohort Study To Assess the Clinical Impact of a Laboratory Based Classification.. <i>Blood</i> , <b>2004</b> , 104, 1056-1056	2.2	
44	High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 4483-8	2.2	272
43	Cladribine therapy for systemic mastocytosis. <i>Blood</i> , <b>2003</b> , 102, 4270-6	2.2	185
42	Identification of RUNX1/AML1 as a classical tumor suppressor gene. <i>Oncogene</i> , <b>2003</b> , 22, 538-47	9.2	61
41	Involved-field radiotherapy for advanced Hodgkin@ lymphoma. <i>New England Journal of Medicine</i> , <b>2003</b> , 348, 2396-406	59.2	255
40	Therapy for stage I aggressive non-Hodgkin@ lymphoma. <i>Croatian Medical Journal</i> , <b>2002</b> , 43, 546-9	1.6	

39	Autologous stem cell transplantation in treatment of aggressive non-Hodgkin $\otimes$ lymphoma. <i>Croatian Medical Journal</i> , <b>2002</b> , 43, 561-4	1.6	1
38	Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. <i>Blood</i> , <b>2001</b> , 97, 2549-54	2.2	379
37	Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. <i>Blood</i> , <b>2001</b> , 98, 3074-81	2.2	275
36	The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. <i>British Journal of Haematology</i> , <b>2001</b> , 112, 950-8	4.5	174
35	Expression of co-stimulatory and adhesion molecules and chemokine or apoptosis receptors on acute myeloid leukaemia: high CD40 and CD11a expression correlates with poor prognosis. <i>British Journal of Haematology</i> , <b>2001</b> , 115, 298-308	4.5	29
34	On the use of Cox regression in the presence of an irregularly observed time-dependent covariate. <i>Statistics in Medicine</i> , <b>2001</b> , 20, 3817-29	2.3	29
33	Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma. <i>Laboratory Investigation</i> , <b>2001</b> , 81, 419-26	5.9	139
32	Successful outcome with a "quintuple approach" of posttransplant lymphoproliferative disorder. <i>Transplantation</i> , <b>2001</b> , 71, 47-52	1.8	31
31	Different age limits for elderly patients with indolent and aggressive non-hodgkin lymphoma and the role of relative survival with increasing age. <i>Cancer</i> , <b>2000</b> , 89, 2667-76	6.4	36
30	The generation of dendritic-like cells with increased allostimulatory function from acute myeloid leukemia cells of various FAB subclasses. <i>Human Immunology</i> , <b>2000</b> , 61, 565-74	2.3	57
29	Complete Remission of Accelerated Phase Chronic Myeloid Leukemia by Treatment With Leukemia-Reactive Cytotoxic T Lymphocytes. <i>Blood</i> , <b>1999</b> , 94, 1201-1208	2.2	243
28	Hairy Cell Leukemia-Specific Recognition by Multiple Autologous HLA-DQ or DP-Restricted T-Cell Clones. <i>Blood</i> , <b>1999</b> , 93, 251-259	2.2	14
27	Mismatched transplants for refractory lymphoma?. <i>Lancet, The</i> , <b>1999</b> , 353, 1725-6	4.0	2
26	Hairy Cell Leukemia-Specific Recognition by Multiple Autologous HLA-DQ or DP-Restricted T-Cell Clones. <i>Blood</i> , <b>1999</b> , 93, 251-259	2.2	1
25	Complete Remission of Accelerated Phase Chronic Myeloid Leukemia by Treatment With Leukemia-Reactive Cytotoxic T Lymphocytes. <i>Blood</i> , <b>1999</b> , 94, 1201-1208	2.2	6
24	Treatment, patterns of failure, and survival of patients with Stage I nodal and extranodal non-Hodgkin $\otimes$ lymphomas, according to data in the population-based registry of the Comprehensive Cancer Centre West. <i>Cancer</i> , <b>1998</b> , 83, 1612-9	6.4	12
23	A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. <i>Journal of the National Cancer Institute</i> , <b>1998</b> , 90, 850-8	9.7	610
22	DNA Fiber Fluorescence In Situ Hybridization Analysis of Immunoglobulin Class Switching in B-Cell Neoplasia: Aberrant CH Gene Rearrangements in Follicle Center-Cell Lymphoma. <i>Blood</i> , <b>1998</b> , 92, 2871-2878	2.2	77

21	Correction of Abnormal T-Cell Receptor Repertoire During Interferon- $\gamma$ Therapy in Patients With Hairy Cell Leukemia. <i>Blood</i> , <b>1998</b> , 91, 4224-4231	2.2	22
20	DNA Fiber Fluorescence In Situ Hybridization Analysis of Immunoglobulin Class Switching in B-Cell Neoplasia: Aberrant CH Gene Rearrangements in Follicle Center-Cell Lymphoma. <i>Blood</i> , <b>1998</b> , 92, 2871-2878	2.2	2
19	Correction of Abnormal T-Cell Receptor Repertoire During Interferon- $\gamma$ Therapy in Patients With Hairy Cell Leukemia. <i>Blood</i> , <b>1998</b> , 91, 4224-4231	2.2	2
18	Gastric lymphomas compared with lymph node lymphomas in a population-based registry differ in stage distribution and dissemination patterns but not in patient survival. <i>Cancer</i> , <b>1997</b> , 79, 390-7	6.4	24
17	Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. <i>New England Journal of Medicine</i> , <b>1995</b> , 332, 1045-51	59.2	241
16	IgD class switching: identification of a novel recombination site in neoplastic and normal B cells. <i>European Journal of Immunology</i> , <b>1995</b> , 25, 3504-8	6.1	45
15	Somatic pairing of centromeres and short arms of chromosome 15 in the hematopoietic and lymphoid system. <i>Human Genetics</i> , <b>1993</b> , 92, 577-82	6.3	35
14	Response to interferon alfa-2b in a patient with systemic mastocytosis. <i>New England Journal of Medicine</i> , <b>1992</b> , 326, 619-23	59.2	192
13	Granulocytic sarcoma (chloroma). Presentation of an unusual case. <i>American Journal of Clinical Pathology</i> , <b>1991</b> , 95, 567-71	1.9	27
12	Hairy Cell Leukemia and Its T Cell Interactions. <i>Leukemia and Lymphoma</i> , <b>1991</b> , 4, 159-66	1.9	9
11	Characterization of a New Human B Cell Line (Bonna-12) with Trisomy 9 and Trisomy 12 Chromosomal Abnormality. <i>Leukemia and Lymphoma</i> , <b>1991</b> , 5, 415-22	1.9	2
10	Discordant morphologic characteristics of B-cell lymphomas in bone marrow and lymph node biopsies. <i>American Journal of Clinical Pathology</i> , <b>1990</b> , 94, 59-66	1.9	35
9	No difference between cytochemical and immunological detection of myeloperoxidase in AML. <i>British Journal of Haematology</i> , <b>1990</b> , 75, 630-1	4.5	6
8	Clinical course and pathologic features of conjunctival non-Hodgkin's lymphoma. A report of six cases. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>1990</b> , 228, 246-51	3.8	6
7	Haematopoietic and immunologic abnormalities in severe aplastic anaemia patients treated with anti-thymocyte globulin. <i>British Journal of Haematology</i> , <b>1989</b> , 71, 421-30	4.5	17
6	Comparison between clonogenic and cytotoxic assays for measuring LAK cell activity. <i>International Journal of Cell Cloning</i> , <b>1989</b> , 7, 232-41		5
5	Bone marrow histopathology of patients with severe aplastic anaemia before treatment and at follow-up. <i>British Journal of Haematology</i> , <b>1989</b> , 72, 439-44	4.5	19
4	Evolution of acquired severe aplastic anaemia to myelodysplasia and subsequent leukaemia in adults. <i>British Journal of Haematology</i> , <b>1988</b> , 70, 55-62	4.5	107

- 3 T-cell prolymphocytic leukemia with an unusual phenotype CD4+ CD8+. *Cancer*, **1987**, 60, 794-803 6.4 6
- 2 Characterization of normal and regenerating bone marrow cells with a panel of monoclonal antibodies. *Scandinavian Journal of Haematology*, **1986**, 36, 71-8 15
- 1 No preferential sensitivity of clonogenic AML cells to ASTA-Z-7557. *Leukemia Research*, **1984**, 8, 723-8 2.7 24